Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.

Iwamoto N, Takanashi M, Yokoyama K, Yonezawa A, Denda M, Hashimoto M, Tanaka M, Ito H, Matsuura M, Yamamoto S, Honzawa Y, Matsubara K, Shimada T.

J Immunol Methods. 2019 Sep;472:44-54. doi: 10.1016/j.jim.2019.06.014. Epub 2019 Jun 12.

2.

A Minimal Physiologically-Based Pharmacokinetic Model for Tacrolimus in Living-Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype.

Itohara K, Yano I, Tsuzuki T, Uesugi M, Nakagawa S, Yonezawa A, Okajima H, Kaido T, Uemoto S, Matsubara K.

CPT Pharmacometrics Syst Pharmacol. 2019 May 14. doi: 10.1002/psp4.12420. [Epub ahead of print]

3.

Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report.

Masui S, Yonezawa A, Izawa K, Hayakari M, Asakura K, Taniguchi R, Isa M, Shibata H, Yasumi T, Nishikomori R, Takita J, Matsubara K.

J Pharm Health Care Sci. 2019 May 2;5:9. doi: 10.1186/s40780-019-0136-4. eCollection 2019.

4.

Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin's Lymphoma.

Yonezawa A, Otani Y, Kitano T, Mori M, Masui S, Isomoto Y, Tsuda M, Imai S, Ikemi Y, Denda M, Sato Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Hayakari M, Takaori-Kondo A, Matsubara K.

Pharm Res. 2019 Apr 15;36(6):82. doi: 10.1007/s11095-019-2624-5.

PMID:
30989405
5.

A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma.

Yoshimitsu M, Utsunomiya A, Fuji S, Fujiwara H, Fukuda T, Ogawa H, Takatsuka Y, Ishitsuka K, Yokota A, Okumura H, Ishii K, Nishikawa A, Eto T, Yonezawa A, Miyashita K, Tsukada J, Tanaka J, Atsuta Y, Kato K; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Bone Marrow Transplant. 2019 Aug;54(8):1266-1274. doi: 10.1038/s41409-018-0400-5. Epub 2018 Dec 13.

PMID:
30546068
6.

Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery.

Katada Y, Nakagawa S, Nishimura A, Sato YK, Taue H, Matsumura K, Yamazaki K, Minakata K, Yano I, Omura T, Imai S, Yonezawa A, Sato Y, Nakagawa T, Minatoya K, Matsubara K.

Eur J Clin Pharmacol. 2019 Apr;75(4):561-568. doi: 10.1007/s00228-018-2592-4. Epub 2018 Nov 21.

PMID:
30460405
7.

Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.

Iwamoto N, Yonezawa A, Matsubara K, Shimada T.

J Pharm Biomed Anal. 2019 Feb 5;164:467-474. doi: 10.1016/j.jpba.2018.11.019. Epub 2018 Nov 8.

PMID:
30447535
8.

Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis.

Nakagawa S, Nakaishi M, Hashimoto M, Ito H, Yamamoto W, Nakashima R, Tanaka M, Fujii T, Omura T, Imai S, Nakagawa T, Yonezawa A, Imai H, Mimori T, Matsubara K.

PLoS One. 2018 Nov 2;13(11):e0206943. doi: 10.1371/journal.pone.0206943. eCollection 2018.

9.

Ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson's disease.

Omura T, Matsuda H, Nomura L, Imai S, Denda M, Nakagawa S, Yonezawa A, Nakagawa T, Yano I, Matsubara K.

Biochem Biophys Res Commun. 2018 Nov 30;506(3):516-521. doi: 10.1016/j.bbrc.2018.10.094. Epub 2018 Oct 22.

PMID:
30361093
10.

Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts.

Sumi E, Nomura T, Asada R, Uozumi R, Tada H, Amino Y, Sawada T, Yonezawa A, Hagiwara M, Kabashima K.

Clin Drug Investig. 2019 Jan;39(1):55-61. doi: 10.1007/s40261-018-0712-7.

11.

Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.

Tsuda M, Otani Y, Yonezawa A, Masui S, Ikemi Y, Denda M, Sato Y, Nakagawa S, Omura T, Imai S, Nakagawa T, Hayakari M, Matsubara K.

Biol Pharm Bull. 2018 Nov 1;41(11):1716-1721. doi: 10.1248/bpb.b18-00491. Epub 2018 Aug 30.

12.

Oxicam-derived non-steroidal anti-inflammatory drugs suppress 1-methyl-4-phenyl pyridinium-induced cell death via repression of endoplasmic reticulum stress response and mitochondrial dysfunction in SH-SY5Y cells.

Omura T, Sasaoka M, Hashimoto G, Imai S, Yamamoto J, Sato Y, Nakagawa S, Yonezawa A, Nakagawa T, Yano I, Tasaki Y, Matsubara K.

Biochem Biophys Res Commun. 2018 Sep 18;503(4):2963-2969. doi: 10.1016/j.bbrc.2018.08.078. Epub 2018 Aug 11.

PMID:
30107908
13.

Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum.

Iwamoto N, Yokoyama K, Takanashi M, Yonezawa A, Matsubara K, Shimada T.

Pharmacol Res Perspect. 2018 Jul 24;6(4):e00422. doi: 10.1002/prp2.422. eCollection 2018 Jul.

14.

Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.

Iwamoto N, Yokoyama K, Takanashi M, Yonezawa A, Matsubara K, Shimada T.

Curr Pharm Biotechnol. 2018;19(6):495-505. doi: 10.2174/1389201019666180703093517.

15.

Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation.

Iwasaki M, Yano I, Fukatsu S, Hashi S, Yamamoto Y, Sugimoto M, Fukudo M, Masuda S, Nakagawa S, Yonezawa A, Kaido T, Uemoto S, Matsubara K.

Ther Drug Monit. 2018 Dec;40(6):675-681. doi: 10.1097/FTD.0000000000000551.

PMID:
29965882
16.

A therapeutic angiogenesis of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel sheets in a canine chronic myocardial infarction model.

Kumagai M, Minakata K, Masumoto H, Yamamoto M, Yonezawa A, Ikeda T, Uehara K, Yamazaki K, Ikeda T, Matsubara K, Yokode M, Shimizu A, Tabata Y, Sakata R, Minatoya K.

Heart Vessels. 2018 Oct;33(10):1251-1257. doi: 10.1007/s00380-018-1185-6. Epub 2018 May 14.

PMID:
29761379
17.

Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients.

Yoshimura K, Yano I, Yamamoto T, Kondo T, Kawanishi M, Isomoto Y, Yonezawa A, Takaori-Kondo A, Matsubara K.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1441-1448. doi: 10.1016/j.bbmt.2018.01.040. Epub 2018 Feb 7.

18.

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy.

Onaka T, Kitagawa T, Kawakami C, Yonezawa A.

Turk J Haematol. 2018 May 25;35(2):135-136. doi: 10.4274/tjh.2017.0448. Epub 2018 Feb 2. No abstract available.

19.

Riboflavin Transporters RFVT/SLC52A Mediate Translocation of Riboflavin, Rather than FMN or FAD, across Plasma Membrane.

Jin C, Yao Y, Yonezawa A, Imai S, Yoshimatsu H, Otani Y, Omura T, Nakagawa S, Nakagawa T, Matsubara K.

Biol Pharm Bull. 2017;40(11):1990-1995. doi: 10.1248/bpb.b17-00292.

20.

Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation.

Yoshimura K, Yano I, Yamamoto T, Kawanishi M, Isomoto Y, Yonezawa A, Kondo T, Takaori-Kondo A, Matsubara K.

Bone Marrow Transplant. 2018 Jan;53(1):44-51. doi: 10.1038/bmt.2017.213. Epub 2017 Oct 9.

PMID:
28991252
21.

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms.

Imai S, Koyanagi M, Azimi Z, Nakazato Y, Matsumoto M, Ogihara T, Yonezawa A, Omura T, Nakagawa S, Wakatsuki S, Araki T, Kaneko S, Nakagawa T, Matsubara K.

Sci Rep. 2017 Jul 20;7(1):5947. doi: 10.1038/s41598-017-05784-1.

22.

Exogenous proline enhances the sensitivity of Tobacco BY-2 cells to arsenate.

Nahar MN, Islam MM, Hoque MA, Yonezawa A, Prodhan MY, Nakamura T, Nakamura Y, Munemasa S, Murata Y.

Biosci Biotechnol Biochem. 2017 Sep;81(9):1726-1731. doi: 10.1080/09168451.2017.1340088. Epub 2017 Jun 16.

PMID:
28622092
23.

Efficacy of protocol-based pharmacotherapy management on anticoagulation with warfarin for patients with cardiovascular surgery.

Katada Y, Nakagawa S, Minakata K, Odaka M, Taue H, Sato Y, Yonezawa A, Kayano Y, Yano I, Nakatsu T, Sakamoto K, Uehara K, Sakaguchi H, Yamazaki K, Minatoya K, Sakata R, Matsubara K.

J Clin Pharm Ther. 2017 Oct;42(5):591-597. doi: 10.1111/jcpt.12560. Epub 2017 May 15.

PMID:
28503837
24.

Rapidly progressive hemorrhagic pneumonia caused by Stenotrophomonas maltophilia occurring early after bone marrow transplantation in a patient with myelodysplastic syndrome.

Katayama O, Kitagawa T, Onaka T, Yonezawa A.

Rinsho Ketsueki. 2017;58(4):323-325. doi: 10.11406/rinketsu.58.323. Japanese.

PMID:
28484160
25.

Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant.

Onaka T, Takahashi N, Miura M, Yonezawa A.

Clin Case Rep. 2017 Mar 17;5(5):605-607. doi: 10.1002/ccr3.900. eCollection 2017 May.

26.

Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data.

Takeuchi M, Yano I, Ito S, Sugimoto M, Yamamoto S, Yonezawa A, Ikeda A, Matsubara K.

Ther Drug Monit. 2017 Apr;39(2):124-131. doi: 10.1097/FTD.0000000000000383.

PMID:
28230619
27.

Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.

Nishikawa Y, Funakoshi T, Horimatsu T, Miyamoto S, Matsubara T, Yanagita M, Nakagawa S, Yonezawa A, Matsubara K, Muto M.

Cancer Chemother Pharmacol. 2017 Mar;79(3):629-633. doi: 10.1007/s00280-017-3249-1. Epub 2017 Feb 15.

PMID:
28204913
28.

Optimal first coil selection to avoid aneurysmal recanalization in endovascular intracranial aneurysmal coiling.

Neki H, Kohyama S, Otsuka T, Yonezawa A, Ishihara S, Yamane F.

J Neurointerv Surg. 2018 Jan;10(1):50-54. doi: 10.1136/neurintsurg-2016-012877. Epub 2017 Jan 27.

PMID:
28130502
29.

Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.

Otani Y, Yonezawa A, Tsuda M, Imai S, Ikemi Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Matsubara K.

PLoS One. 2017 Jan 4;12(1):e0169588. doi: 10.1371/journal.pone.0169588. eCollection 2017.

30.

Herpes zoster duplex bilateralis in bortezomib-based chemotherapy.

Onaka T, Yonezawa A.

Blood Res. 2016 Sep;51(3):155. Epub 2016 Sep 23. No abstract available.

31.

An Analysis of the Educational Effects of Studying Basic Life Support.

Watanabe T, Itoh K, Yonezawa A.

Yakugaku Zasshi. 2016;136(9):1319-23. doi: 10.1248/yakushi.16-00019. Japanese.

32.

Disseminated Mycobacterium abscessus Complex Infection Manifesting as Multiple Areas of Lymphadenitis and Skin Abscess in the Preclinical Stage of Acute Lymphocytic Leukemia.

Tahara M, Yatera K, Yamasaki K, Orihashi T, Hirosawa M, Ogoshi T, Noguchi S, Nishida C, Ishimoto H, Yonezawa A, Tsukada J, Mukae H.

Intern Med. 2016;55(13):1787-91. doi: 10.2169/internalmedicine.55.6759. Epub 2016 Jul 1.

33.

Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice.

Yoshimatsu H, Yonezawa A, Yamanishi K, Yao Y, Sugano K, Nakagawa S, Imai S, Omura T, Nakagawa T, Yano I, Masuda S, Inui K, Matsubara K.

Sci Rep. 2016 Jun 8;6:27557. doi: 10.1038/srep27557.

34.

Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.

Yonezawa A, Chester C, Rajasekaran N, Kohrt HE.

Chin Clin Oncol. 2016 Feb;5(1):5. doi: 10.3978/j.issn.2304-3865.2016.02.05. Review. No abstract available.

35.

Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data.

Ito S, Yano I, Hashi S, Tsuda M, Sugimoto M, Yonezawa A, Ikeda A, Matsubara K.

Ther Drug Monit. 2016 Jun;38(3):371-8. doi: 10.1097/FTD.0000000000000291.

PMID:
26913593
36.

[Extranodal natural killer/T-cell lymphoma, nasal type developing central nervous system and epididymis involvement immediately after concurrent chemoradiotherapy].

Sasaki Y, Yonezawa A, Kinoshita Y, Kitagawa T, Mori M, Onaka T, Imada K.

Rinsho Ketsueki. 2015 Dec;56(12):2472-6. doi: 10.11406/rinketsu.56.2472. Japanese.

PMID:
26725358
37.

[Infliximab therapy for Crohn's-like gastrointestinal lesions after allogeneic bone marrow transplantation].

Onaka T, Kitagawa T, Mori M, Yonezawa A, Imada K.

Rinsho Ketsueki. 2015 Dec;56(12):2452-5. doi: 10.11406/rinketsu.56.2452. Japanese.

PMID:
26725354
38.

A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head.

Kuroda Y, Asada R, So K, Yonezawa A, Nankaku M, Mukai K, Ito-Ihara T, Tada H, Yamamoto M, Murayama T, Morita S, Tabata Y, Yokode M, Shimizu A, Matsuda S, Akiyama H.

Int Orthop. 2016 Aug;40(8):1747-1754. doi: 10.1007/s00264-015-3083-1. Epub 2015 Dec 29.

39.

Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach.

Yoshimura K, Yano I, Kawanishi M, Nakagawa S, Yonezawa A, Matsubara K.

Drug Metab Pharmacokinet. 2015 Dec;30(6):441-8. doi: 10.1016/j.dmpk.2015.10.004. Epub 2015 Nov 3.

PMID:
26643991
40.

Prevalence and clinical characteristics of degenerative mitral stenosis.

Ukita Y, Yuda S, Sugio H, Yonezawa A, Takayanagi Y, Masuda-Yamamoto H, Tanaka-Saito N, Ohnishi H, Miura T.

J Cardiol. 2016 Sep;68(3):248-52. doi: 10.1016/j.jjcc.2015.09.021. Epub 2015 Nov 3.

41.

Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.

Koyama S, Omura T, Yonezawa A, Imai S, Nakagawa S, Nakagawa T, Yano I, Matsubara K.

PLoS One. 2015 Aug 19;10(8):e0136176. doi: 10.1371/journal.pone.0136176. eCollection 2015.

42.

Clinical and echocardiographic characteristics for differentiating between transthyretin-related and light-chain cardiac amyloidoses.

Mori M, An Y, Katayama O, Kitagawa T, Sasaki Y, Onaka T, Yonezawa A, Murata K, Yokota T, Ando K, Imada K.

Ann Hematol. 2015 Nov;94(11):1885-90. doi: 10.1007/s00277-015-2466-0. Epub 2015 Aug 8.

PMID:
26251157
43.

[Successful second cord blood transplantation (CBT) for late graft failure associated with several immune disorders after the initial CBT in a patient with acute myeloid leukemia].

Mori M, Yonezawa A, Kitagawa T, Sasaki Y, Onaka T, Imada K.

Rinsho Ketsueki. 2015 Jul;56(7):889-94. doi: 10.11406/rinketsu.56.889. Japanese.

PMID:
26251154
44.

[The Contribution of GMP-grade Hospital Preparation to Translational Research].

Yonezawa A, Kajiwara M, Minami I, Omura T, Nakagawa S, Matsubara K.

Yakugaku Zasshi. 2015;135(8):943-7. doi: 10.1248/yakushi.15-00112-3. Review. Japanese.

45.

Yersiniosis due to infection by Yersinia pseudotuberculosis 4b in captive meerkats (Suricata suricatta) in Japan.

Nakamura S, Hayashidani H, Yonezawa A, Suzuki I, Une Y.

J Vet Diagn Invest. 2015 Sep;27(5):641-4. doi: 10.1177/1040638715596035. Epub 2015 Jul 15.

PMID:
26179097
46.

A novel protocol for antibiotic prophylaxis based on preoperative kidney function in patients undergoing open heart surgery under cardiopulmonary bypass.

Odaka M, Minakata K, Toyokuni H, Yamazaki K, Yonezawa A, Sakata R, Matsubara K.

Gen Thorac Cardiovasc Surg. 2015 Aug;63(8):446-52. doi: 10.1007/s11748-015-0552-9. Epub 2015 Apr 30.

PMID:
25925714
47.

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.

Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE.

Clin Cancer Res. 2015 Jul 15;21(14):3113-20. doi: 10.1158/1078-0432.CCR-15-0263. Epub 2015 Apr 23. Review.

48.

Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury.

Nakano K, Ando H, Kurokawa S, Hosohata K, Ushijima K, Takada M, Tateishi M, Yonezawa A, Masuda S, Matsubara K, Inui K, Morita T, Fujimura A.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1191-7. doi: 10.1007/s00280-015-2743-6. Epub 2015 Apr 11.

PMID:
25862351
49.

Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia.

Kumagai M, Marui A, Tabata Y, Takeda T, Yamamoto M, Yonezawa A, Tanaka S, Yanagi S, Ito-Ihara T, Ikeda T, Murayama T, Teramukai S, Katsura T, Matsubara K, Kawakami K, Yokode M, Shimizu A, Sakata R.

Heart Vessels. 2016 May;31(5):713-21. doi: 10.1007/s00380-015-0677-x. Epub 2015 Apr 11.

PMID:
25861983
50.

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.

Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt HE.

Immunotargets Ther. 2015 May 15;4:91-100. doi: 10.2147/ITT.S61292. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center